HEALEY ALS Platform Trial

Date Added
June 23rd, 2020
PRO Number
Pro00099528
Researcher
Amy Chen

List of Studies


Keywords
Brain, Drug Studies, Nervous System, Rare Diseases
Summary

The HEALEY ALS Platform Trial is a research trial that tests the safety and effectiveness of multiple treatment courses on Amyotrophic Lateral Sclerosis (ALS). Different courses of treatments may be ongoing at the same time and additional treatment courses may be added to the study as time goes by. Qualified participants will have a 3 in 4 chance of being randomly assigned to an active drug or a 1 in 4 chance of being randomly assigned to an inactive drug. After a treatment course is completed, participants may participate in another treatment course, or if available, continue in an optional extension period of the treatment.

Institution
MUSC
Recruitment Contact
Lauren Card
843-729-4394
cardl@musc.edu

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis

Date Added
September 24th, 2019
PRO Number
Pro00092083
Researcher
Amy Chen

List of Studies


Keywords
Muscle, Nervous System
Summary

Myasthenia gravis (MG) is a serious, sometimes life threatening, debilitating condition associated with numerous symptoms including muscular weakness and fatigue. This study is to see how effective and safe rozanolixizumab is in adult patients experiencing moderate to severe symptoms of generalized myasthenia gravis (gMG).

The study consists of a Screening Period of up to 4 weeks, followed by a 6-week double-blind Treatment Period and an Observation Period of 8 weeks. During this 18 weeks period there will be 14 visits to the study clinic.

Institution
MUSC
Recruitment Contact
Aparna Choudhury
843-792-7450
choudhur@musc.edu

Radicava, (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Date Added
September 13th, 2019
PRO Number
Pro00089696
Researcher
Amy Chen

List of Studies


Keywords
Nervous System
Summary

Adult patients with ALS that have been recently perscribed Edaravone may qualify to participate in this observational study. Blood and urine samples will be collected to evaluate the effects of Edaravone on ALS and the severity of ALS. During an estimated 12-month period, eligible participants will have approximately 15 clinic visits.

Institution
MUSC
Recruitment Contact
Katrina Madden
843-792-9186
maddenka@musc.edu



-- OR --